NCT00947687已完成1 期
A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.
研究概览
简要总结
The objectives of the study are to demonstrate the effectiveness, safety and tolerability of multiple daily doses of inhaled PUR003, in comparison with placebo, in healthy adults experimentally inoculated with Influenza A/Wisconsin/67/2005 (H3N2) virus.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects aged 18 to 45 years.
- •In general good health determined by a screening evaluation ≤120 days prior to double-blind IMP administration and on the day of admittance to quarantine.
- •Seronegative (NDA) for challenge virus.
- •Have not been vaccinated for influenza virus since 2006 (as determined in the medical history) or had a known influenza infection in the current season, defined as in the last 12 months.
排除标准
- •Presence or evidence of significant acute or chronic, uncontrolled medical or psychiatric illness.
- •Abnormal pulmonary function as evidenced by clinically significant abnormality in spirometry.
- •Health care workers (including doctors, nurses, medical students and allied healthcare professionals) anticipated to have patient contact within two weeks of discharge from quarantine.
- •Intending to travel (to countries for which vaccinations are recommended or where high risk of infections exists).
- •Presence of household member or close contact (until 14 days after discharge from quarantine) who is: less than 3 years of age; has any known immunodeficiency; is receiving immunosuppressant medications; is undergoing or soon to undergo cancer chemotherapy within 28 days of challenge.
- •Subjects with diagnosed emphysema or chronic obstructive pulmonary disease (COPD); elderly residing in a nursing home, affected by severe lung disease or medical condition; or a transplant (bone marrow or solid organ) organ recipient
- •Subjects with any history of asthma, COPD, pulmonary hypertension, reactive airway disease, or any chronic lung condition of any aetiology.
- •Regular daily smokers during the 6 months prior to study entry or those who have a significant history of any tobacco use at any time (≥ total 10 pack year history = one pack a day for 10 years).
- •Presence of any febrile illness or symptoms of upper or lower tract respiratory infection in the 28 days prior to viral inoculation (such subjects may be re-evaluated for enrolment after resolution of the illness).
- •Receipt of any investigational drug within 3 months, or prior participation in a clinical trial of any influenza vaccine or medication within 1 year of participation.
研究组 & 干预措施
PUR003
Experimental
干预措施: PUR003 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.
时间窗: Day 6
次要结局
- Quantitative viral shedding from nasal viral inoculation until day 6(Day 0 to day 6)
- Subjected-reported symptom scores assessed both individually and as a composite score evaluating severity overall and at the time of peak symptom score(Day 6 of study)
- Change in bioaerosol output with treatment and after viral inoculation(Day -2 to day 6)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male SubjectsHealthyNCT01473173HK inno.N Corporation59
已完成
1 期
Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's AtaxiaFriedreich's AtaxiaNCT01898884Shire46
已完成
1 期
A Study of HS-10353 in Chinese Participants.Major Depressive DisorderNCT05195203Jiangsu Hansoh Pharmaceutical Co., Ltd.96
已完成
1 期
Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy ParticipantsHealthy VolunteerNCT03454126Biogen80
Unknown
1 期
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy VolunteersHealthyNCT04652297Jiangsu Hansoh Pharmaceutical Co., Ltd.76